PDCD1 and neoplasm: RXC004 also reduced MDSCs, while increasing overall immune infiltrate into the “cold tumor” B16F10 syngeneic model, which was confirmed to be nonresponsive to anti-PD-1 monotherapy, demonstrating a profound ability of RXC004 to reset aberrant immune responses, consistent with another recent study (36).